Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Outcomes from Deep Brain Stimulation with Multiple Independent Current Control (MICC) in Parkinson's Disease
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
097
To evaluate clinical outcomes of deep brain stimulation (DBS) with multiple independent current control (MICC) in Parkinson's disease (PD) patients following lead implantation using the Boston Scientific Vercise System®. 
DBS of several brain regions (subthalamic nucleus (STN), globus pallidus internus (GPi) and ventral intermediate nucleus of the thalamus (VIM)) effectively improves motor symptoms in appropriately selected patients with PD. Long term follow-up data on devices with MICC is lacking.
Clinical outcomes in 9 patients implanted with the Boston Scientific Vercise System® (linear and directional leads) were reviewed. Unified Parkinson's Disease Rating Scale (UPDRS) III motor scores were obtained at the preoperative visit, and at 9 to 18 months post-activation.

Mean age at surgery was 57.22 ±13 years; the mean time since initial device activation was 12.11 ±2.62 months. Five patients were implanted in the GPi, 3 patients in the STN, and 1 patient in the STN and VIM. The mean preoperative OFF med UPDRS III score was 47.67 ±20. At the post activation visit, the mean OFF stim/OFF meds UPDRS III score was 35.14 ±10.60, while mean ON stim/OFF meds UPDRS III score was 14.58 ±10.45 (69% improvement from baseline; 59% improvement compared to OFF stim/OFF meds scores at the same visit). The mean Patient Global Impression scale score was 1.75 ±0.89 for 8 patients who responded (1 = Very much improved, 2 = Much improved). Fractionalized stimulation was used in all directional and linear leads ranging from 1 to 6 contacts per lead with a mean of 3.06 ± 1.34 contacts. No stimulation side effects were reported.

At a mean follow-up of one-year post DBS implantation, MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.  Long-term evaluation in ON stim/OFF meds conditions in a larger cohort is planned.
Authors/Disclosures
Alina Shub, PA (University of South Florida)
PRESENTER 		The institution of Ms. Shub has received research support from Abbott and Boston Scientific .
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Theresa A. Zesiewicz, MD (University of South Florida) Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.